BeiGene (BGNE) Reports Q4 Loss of $4.52/ADS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. REGN
3. LITE
4. ABBV
5. AAPL
6. MRVL
7. CL
8. ORCL
9. TFII
10. LYB

Go back to BeiGene (BGNE) Reports Q4 Loss of $4.52/ADS

BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results

February 27, 2019 4:15 PM EST

Company to Host Annual Results Conference Call Today at 6:00 p.m. EST

and Investor Event in Hong Kong on February 28th at 2:30 p.m. HKT

CAMBRIDGE, Mass. and BEIJING, China, Feb. 27, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights, anticipated upcoming milestones, and financial results for the fourth quarter and full year of 2018.

Building on a strong foundation, in 2018 we... More